Glycemic control in type 1 diabetes (T1D) remains a challenge, with only ~20% of American adults and ~30% of Europeans achieving a hemoglobin A1c (HbA1c) target of <7%, despite the availability of modern insulin analogs, the improving accuracy of continuous glucose monitoring (CGM), the widening use of intensive insulin therapy, and the emerging use of Hybrid Automated Insulin Delivery (hAID) systems. While new technologies have proven benefits in avoiding diabetes-related complications and may have reduced excess mortality in some populations, excess mortality and complication rates remain higher in Type 1 Diabetes (T1D) when compared to the general population.

This study (ClinicalTrials.gov: NCT07087340) will assess the early feasibility of the recently developed UBLoop system, the first Swiss Automated Insulin Delivery (AID) system, through a 10-hour supervised visit that includes two meal challenges. In this study, we will recruit up to six participants with type 1 diabetes to assess the system’s stability during the main visit, focusing on the percentage of time in closed-loop mode, failure rate of the UBLoop algorithm, failure rate of communication with the CGM sensor and insulin pump, failure rate of the web monitoring tool (DigiCARE), and dailure rate of the dedicated app interface.